By modulating APP processing, BACE1 expression, and autophagic clearance, S6K1 inhibition emerges as a promising therapeutic strategy for reducing Aβ accumulation and rescuing cognitive decline in AD. This evidence concerns the gene RPS6KB1 and Alzheimer disease.